WO2020111402A1 - Huile de bourrache traitée par enzyme contenant une concentration élevée d'acide gamma-linolénique libre ayant un effet d'amélioration sur la perte de cheveux élevé, son procédé de préparation et composition cosmétique la contenant - Google Patents

Huile de bourrache traitée par enzyme contenant une concentration élevée d'acide gamma-linolénique libre ayant un effet d'amélioration sur la perte de cheveux élevé, son procédé de préparation et composition cosmétique la contenant Download PDF

Info

Publication number
WO2020111402A1
WO2020111402A1 PCT/KR2019/004499 KR2019004499W WO2020111402A1 WO 2020111402 A1 WO2020111402 A1 WO 2020111402A1 KR 2019004499 W KR2019004499 W KR 2019004499W WO 2020111402 A1 WO2020111402 A1 WO 2020111402A1
Authority
WO
WIPO (PCT)
Prior art keywords
enzyme
treated
borage oil
hair loss
linolenic acid
Prior art date
Application number
PCT/KR2019/004499
Other languages
English (en)
Korean (ko)
Inventor
정종문
이승숙
오현근
박수영
Original Assignee
주식회사 벤스랩
정종문
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 벤스랩, 정종문 filed Critical 주식회사 벤스랩
Publication of WO2020111402A1 publication Critical patent/WO2020111402A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone

Definitions

  • the present invention relates to an enzyme-treated borage oil containing a high concentration of free gamma-linolenic acid having a high hair loss improvement effect, a method for manufacturing the same, and a cosmetic composition comprising the same, in particular, by treating the borage oil having a high content of gamma-linolenic acid 5 Alpha-reducing enzyme to inhibit the high hair loss improvement effect, that is, hair loss and hair follicle cell recovery high-concentration free gamma-linolenic acid-containing enzyme-containing borage oil, relates to a preparation method and a cosmetic composition comprising the same.
  • the number of human hair is estimated to be approximately 100,000 to 150,000. It is said that 50 to 100 hairs are lost per day, and hair loss has started when more than 100 hairs are lost per day.
  • the causes of hair loss are very diverse, and the pattern varies from person to person. In particular, men's hair tends to become thinner and thinner in their 20s.
  • Male Pattern Baldness (MPB) which is the most common symptom among hair loss symptoms, has a large genetic characteristic, and another major reason is that the hair roots weaken due to abnormal male hormones and excessive sebum secretion causes inflammation of the scalp. Hair falls out.
  • the most common cause of male pattern hair loss (about 90% or more) is an abnormality of male hormone (androgenic alopecia).
  • male hormone androgenic alopecia
  • prostatic hyperplasia when the dihydrotestosterone is over-synthesized by 5-alpha reductase, the dihydrotestosterone binds to the androgen receptors around the hair follicles, gradually shrinking and degrading the hair follicles, eventually reducing the period of hair growth. Because of the reduced growth period, the roots of the hair, that is, the hair follicles, do not develop sufficiently and at the same time, the pigment accumulation is also insufficient. Hairless immature hair often comes out of the scalp and eventually hair loss begins.
  • the shrinking hair follicles eventually die and permanent hair loss occurs, which makes treatment other than hair transplantation difficult.
  • Dihydrotestosterone provides a factor that makes the size of the hair smaller and smaller as the growth period is shortened and the rest period is shortened during the hair growth cycle.
  • the hair follicles contract more and more, and instead, the sebaceous glands become larger and smaller, making the hair thinner and smaller, and, as a rule, more oily, causing rashes or inflammation.
  • the thin and small hair turns into fluffy and becomes invisible to our eyes, and the scalp in the head begins to be seen.
  • Testosterone is primarily known to affect the growth of underarm hair and pubic hair, while dihydrotestosterone is known to affect beard and baldness, but it is not clear.
  • Drugs for treating prostatic hyperplasia and male pattern hair loss are also known. However, it is most important to inhibit 5-alpha reductase for fundamental treatment.
  • 5-alpha reductase synthesis inhibitors include finasteride and dutasteride. Testosterone is converted into dihydrotestosterone by 5-alpha reductase in the prostate tissue. Therefore, taking a 5-alpha reductase inhibitor that effectively prevents the conversion of dihydrotestosterone can reduce the size of the prostate. It is known that the size of the prostate is reduced to the maximum after approximately 6 months of use. Finasteride, a competitive inhibitor of 5-alpha reductase developed by Merck, also inhibits type 1, but mainly inhibits type 2 5-alpha reductase, thereby reducing dihydrotestosterone in the prostate and blood.
  • Dutasteride has a longer half-life than finasteride, and is 45 times stronger for type 1 enzymes and 2.5 times stronger for type 2 enzymes. Most of the liver has metabolism, so use should be limited in patients with liver failure. Synthetic inhibitors of these 5-alpha reductases can be said to be a fundamental treatment method for prostatic hyperplasia, but patients who take 5 mg/day for 4 to 6 months for a long period of time can see the effect, and the problem of recurrence has been suggested. . Erectile dysfunction, decreased libido, gynecomastia, and ejaculation disorders have been reported as side effects.
  • Finasteride is also used to treat male pattern hair loss. Finasteride was originally used to treat prostatic hyperplasia, but the effect of hair loss treatment was also recognized by the US Food and Drug Administration, and the dosage was prescribed at a rate of 1 mg per day and sold as a treatment for hair loss (trade name, Propecia). As mentioned above, this drug also exhibits a hair loss treatment effect through a mechanism for inhibiting 5-alpha reductase present in the scalp. However, at least 3 to 5 months are effective only after taking it and there is a disadvantage of returning to the original state within 12 months if taken and stopped.
  • finasteride itself is similar to sex hormones such as testosterone and progesterone hormones, side effects are often found in women, and particularly, because of the risk of birth defects, the use of mothers is strictly limited. Even factories that produce finasteride prohibit women from participating directly in production.
  • Minoxidil was also developed for the treatment of hypertension, and it was developed and marketed as a hair growth agent after observing hair loss inhibition in hypertensive patients. Although the mechanism of action of minoxidil is not clear, it can be seen that the blood vessels of the scalp are expanded to easily supply oxygen and nutrients to the hair follicle, thereby promoting hair formation and development. There are few side effects, but in order to achieve the maximum effect, it must be applied for a long period of time for 6 months or more, and the effect disappears when it is discontinued. In addition, it is not an inhibitor of 5-alpha reductase, so it cannot lower the concentration of dihydrotestosterone.
  • Herbal therapy has different potential for the treatment of prostatic hyperplasia and male pattern alopecia, but to date, long-term clinical results have not been accumulated compared to the placebo control group.
  • Saw Palmetto which is reported to be used by more than 2 million people in the United States alone, is derived from the fruits of the saw palm tree and is the most common natural-derived functional food used for prostatic hyperplasia.
  • Indians used saw palmetto fruit as a remedy for the genitourinary system.
  • the main components of saw palmetto are triglycerides type fatty acids and phytosterols, which are thought to improve prostate hyperplasia and improve hair loss by acting as a 5-alpha reductase inhibitor.
  • saw palmetto is recognized as an effect of improving prostatic hypertrophy, and is marketed as an individually recognized product.
  • cucurbit seed oil has been used as an active ingredient and has been manufactured and sold as a treatment for prostatic hyperplasia.
  • this seed oil is imported from European pharmaceutical companies as an extract of pumpkin seeds from Europe.
  • the pharmaceutical company explained that cucurbit seed oil cures blood cholesterol causing prostate hypertrophy and prevents changes in male hormones to treat urination disorders caused by prostate hypertrophy.
  • Camellia is also called winter rose and grows in China's Shandong province, Taiwan, South Korea, and Japan. It grows mainly at 300 to 1,100 m above sea level, and is usually about 1.5-6 m tall. It blooms from January to March. It is grown in Tongyeong and Jeju Island in Korea.
  • camellia oil produced in Tongyeong in Korea is imported and sold by a specialized Japanese atopic dermatitis company.
  • Camellia oil is a fatty oil extracted from the seeds of the Camellia japonica L. of the family Theaceae and its constituent fatty acids similar to olive oil, which contains up to 82-86% of oleic acid. It is used for creams, emulsions, etc. for similar purposes, especially for hair.
  • Oleic acid which is high in camellia oil, lowers the level of LDL cholesterol, a low-density cholesterol that is harmful to the body, while increasing the level of HDL cholesterol, a high-density cholesterol that is good for the body, prevents high blood pressure and heart disease. It is known to be effective in preventing cancer and reducing memory due to aging.
  • oleic acid does not exist as a free oleic acid in nature, and is usually covalently attached to glycerol in an ester form.
  • Commercial oleic acid is either a form of K + or Na + consisting of saponification of oil, or an ethyl ester type through ethanolysis, or manufactured through several industrial processes.
  • the present inventors fermented camellia oils containing abundance of essential unsaturated fatty acids oleic acid and linoleic acid to facilitate absorption and use, and oleic acid and linoleic acid released from glycerol skeleton molecules without any other chemical treatment.
  • a 5-alpha-reductase inhibitory ability generated by increasing the content of essential fatty acids, including fermented natural oil, which has the effect of preventing and improving prostatic hyperplasia and male pattern hair loss, and filed it with the Korean Intellectual Property Office to register No. 10-1452320 Patents have been registered.
  • Republic of Korea Patent Application Publication No. 10-2009-0076671 name of the invention: a method for preparing a composition for preventing hair loss and promoting hair growth
  • the present invention is excellent in preventing hair loss, preventing hair loss having a hair growth effect and It relates to a method for preparing a composition for promoting hair growth, alcohol extracts, such as anterior umbilical cord, celestial crown, gangjinhyang, snake beet and coarse, which promote the production of new capillaries among natural products that can improve this in relation to the disappearance and atrophy of hair cells.
  • OxPAPC Oxidized 1-Palmitoyl-2-Arachidonoyl-sn-Glycero-3-Phosphocholine
  • the present invention relates to a composition for preventing hair loss or hair growth promoting comprising phospholipids as an active ingredient It relates to a composition for preventing hair loss or promoting hair growth, which includes phospholipids extracted from animals as an active ingredient.”
  • Republic of Korea Patent Publication No. 10-2012-0102111 No. (invention name: reduction of hair loss and / or hair growth and / or promoting method of hair growth) "The present invention delays hair loss or hair growth and / or hair growth It relates to a method of promoting. More specifically, the present invention relates to a method of using the disclosed composition for increasing the rate of hair growth and/or hair growth in mammals.”
  • the present invention is an enzyme treatment borage that contains a high concentration of free gamma-linolenic acid excellent in hair loss improvement effect, that is, a high hair loss improvement effect by inhibiting 5 alpha-reductase by enzymatic treatment of borage oil with high gamma-linolenic acid content. It is an object to provide an oil, a method for manufacturing the same, and a cosmetic composition comprising the same.
  • Enzyme-treated borage oil containing a high concentration of free gamma-linolenic acid having a high hair loss improvement effect includes enzyme-treated borage oil containing free gamma-linolenic acid by enzymatically treating borage oil with a lipase.
  • an enzyme treatment comprising a high concentration of free gamma-linolenic acid having a high hair loss improvement effect, that is, a high hair loss improvement effect by inhibiting 5 alpha-reductase by enzymatic treatment of borage oil having a high content of gamma-linolenic acid It has an effect of providing borage oil, a method for manufacturing the same, and a cosmetic composition comprising the same.
  • the present invention enzymatically treats borage oil with a high content of gamma-linolenic acid with immobilized lipase, dihydrotestosterone (Dihydrotestosterone, which destroys hair follicle cells through high 5 alpha-reductase inhibitory ability including high concentration free gamma-linolenic acid) DHT) has an object to provide an enzyme-treated borage oil that effectively blocks the production, a manufacturing method thereof, and a cosmetic composition comprising the same.
  • dihydrotestosterone Dihydrotestosterone, which destroys hair follicle cells through high 5 alpha-reductase inhibitory ability including high concentration free gamma-linolenic acid
  • 1 is a graph showing the results of quantifying DHT produced by 5 alpha-reductase as an experimental result of 5 alpha-reductase activity inhibition of free fatty acids.
  • Figure 2 is a graph showing the results of quantifying the DHT produced by the 5 alpha-reductase as a result of comparing the inhibitory ability of the existing 5 alpha-reductase inhibitors saw palmetto and finasteride with enzyme-treated vegetable oil.
  • FIG. 3 is a graph showing the results of measuring the cell viability (%) by dividing the enzyme-treated borage oil into hair follicle cell growth promoting experiments, divided into a general control group and a control group for 0.1% DMSO.
  • FIG. 5 is a test result of an increase in hair growth of testosterone-induced hair loss model rats of enzyme-treated borage oil, and is a photograph showing the progress of the experiment by taking a picture using a digital camera (Nikon D90).
  • FIG. 6 is a criterion for scoring a visual evaluation of hair growth related to FIG. 5.
  • FIG. 7 is a graph showing a result of scoring the progress of FIG. 6 as a reference for scoring of FIG. 6.
  • the present invention provides enzyme-treated borage oil containing high-concentration free gamma-linolenic acid with high hair loss improvement, characterized in that it contains free gamma-linolenic acid by enzymatically treating borage oil with a lipase enzyme. do.
  • the present invention in the best form, in a method for producing enzyme-treated borage oil by enzymatic treatment of borage oil, (1) Borage oil preheated to a temperature within the range of 10 to 40°C to resin Enzyme treatment step of enzymatic treatment under conditions of contact with the immobilized lipase enzyme for 10 to 100 hours; And (2) a fractionation step in which the enzyme treatment obtained by completing the enzyme treatment is mixed with 1,3-butylene glycol, and then dissolved to recover a layer containing fatty acids; It provides a method for producing enzyme-treated borage oil characterized in that it comprises a.
  • Enzyme-treated borage oil containing a high concentration of free gamma-linolenic acid having a high hair loss improvement effect comprises enzymatically treated borage oil containing free gamma-linolenic acid by enzymatically treating borage oil with a lipase It is characterized by.
  • the content of free essential unsaturated fatty acids such as gamma-linolenic acid, alpha-linolenic acid, linoleic acid, oleic acid, etc. is increased through enzymatic treatment, and high concentration of free gamma-linolenic acid with high inhibitory ability against 5 alpha-reductase It is characterized in that it obtains the composition included, thereby providing an improved effect compared to the existing composition for improving hair loss and treatment.
  • the enzyme separated from the strain is immobilized and applied to the enzyme treatment (fermentation) to shorten the production time, simplify the manufacturing process through simplification of purification after enzyme treatment, and minimize the disadvantages of the existing fermentation method by preventing fermentation. Provide a manufacturing process.
  • GLA Gamma-linolenic acid
  • omega 6 fatty acid is an unsaturated fatty acid. It is usually found in vegetable oils, and is found in evening primrose oil, blackcurrant seed oil, and borage oil in nature. It is a substance essential for in vivo synthesis of prostaglandin, which is effective in lowering the level of cholesterol in the blood, and is also known to be effective in lowering blood sugar, anti-inflammatory, anti-cancer, weight-loss, osteoporosis, rheumatoid arthritis, menopause syndrome, and menstrual syndrome.
  • Alpha-linolenic acid is a type of omega 3 fatty acid that is an unsaturated fatty acid. It is a precursor that is converted into ePA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the body.
  • ePA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • alpha-linolenic acid and linoleic acid which is an omega 6 fatty acid, it is known that when it lacks as essential fatty acid that is not synthesized by the human body, it lacks DHA required for the brain and retina, thereby reducing learning and visual functions.
  • Omega 3 fatty acids protect cells in the human body, maintain cell structure and aid in smooth metabolism. In addition, it suppresses the film formation of blood and promotes and strengthens bone formation. It is known that a lack of omega 3 fatty acids leads to a lack of DHA for the brain and retina, leading to a decrease in learning and visual function. According to the recently researched results, clinical research results have been reported that alpha-linolenic acid reduced the C-reactive protein, which is a marker of inflammation, and ingestion of alpha-linolenic acid lowers cholesterol in the blood and reduces the risk of cardiovascular disease. It is known that an effect that a function is protected can be obtained.
  • Linoleic acid is an unsaturated fatty acid with two double bonds, insoluble in water, soluble in ether and alcohol, and used as a source of soft soap. Also called 9,12-octadecadienoic acid. It is contained in soybean oil, cottonseed oil, etc. among vegetable oils by ester bonding with glycerol. Dry oil, which tends to be oxidized in the air, is composed mainly of linoleic acid and linolenic acid. It is found slightly in the animal body as a fatty acid constituting phospholipids. Some animals cannot synthesize on their own and require it as an essential nutrient. It is also called vitamin F (F of fatty acids) along with linolenic acid. It is used as a raw material for soft soap.
  • vitamin F F of fatty acids
  • Oleic acid is a major component of fatty acids in olive oil and is an omega-9 unsaturated fatty acid. It plays a role in lowering blood pressure in olive oil. According to the type of fatty acid, which is a component of triglycerides, it is classified into saturated fatty acids and unsaturated fatty acids, and unsaturated fatty acids are classified into monounsaturated fatty acids and polyunsaturated fatty acids according to the number of carbon double bonds. Oleic acid is a monounsaturated fatty acid that has only one double bond between carbon atoms. It is a fatty acid that is widely found in plants and animals, as well as vegetable oils such as olive oil and canola oil, as well as animal fats such as cattle and pigs.
  • Borage oil is Borage (Scientific name: Borago officinalis )
  • borage oil is known to be rich in gamma-linolenic acid and is known to be effective in lowering blood sugar, anti-inflammatory, weight loss, osteoporosis, and reducing menopausal and menstrual syndrome in women. It is reported to give.
  • the lipase enzyme is enzymatically processed in a batch manner using an immobilized enzyme immobilized on a resin, preferably a lipase derived from the microorganism of the genus Lysopus, and centrifuged. Separating and filtering the enzyme residue and resin by separation, mixing the obtained enzyme treatment solution with 1,3-butylene glycol, and then separating the layer containing the fatty acid and the enzyme-free borage oil.
  • the layer containing the fatty acid can be subsequently processed to be used as a raw material for the cosmetic composition, and the oily layer containing unenzymatic borage oil can be recovered and introduced again into the enzyme treatment process.
  • 1,3-butylene glycol is particularly used to recover the layer containing the fatty acid from the enzyme treatment
  • 1,3-butylene glycol is widely used as a cosmetic raw material, particularly for the enzyme treatment of oil. Not only can it dissolve the fatty acid and glycerol produced by it, it can be used as a solvent for various raw materials for general cosmetics, so a layer containing fatty acids recovered with 1,3-butylene glycol can be used as a cosmetic ingredient as it is.
  • the lipase is inoculated with the microorganism of the genus Rizopus in an amount of 10% by volume relative to the medium volume, and cultured under aerobic conditions, pH 5.5 to 6.5, culture conditions of 25 to 35°C, and 800 to 1 to 10°C
  • the supernatant obtained by centrifugation at 1200 rpm may be precipitated and concentrated by ammonium sulfate, and then may be a dialysate obtained by dialysis, which is used directly as a microorganism by using a culture concentrate of microorganisms of the genus Rizopus
  • the medium may be 2 to 10% by weight of potato starch, 0.5 to 3% by weight of dextrose and PDB (Potato Dextrose Broth) containing water as the remaining amount.
  • Cultivation using the PDB may be preferably performed at a pH of 6.0 ⁇ 0.2 and aerobic conditions, and the PDB preferably further comprises 0.1 to 10% by weight of olive oil based on the total weight of the PDB. have.
  • the fermentation culture time in the culture conditions of the culture concentrate of the genus Rhizopus is the best when it is cultured within the range of 80 to 150 hours.
  • Rhizopus sp Microorganisms are the first genus of fungi of Mucorales , and the stolon spreads and stretches to the side, where it touches the medium, i.e., one to several from the node. Sporangia and rhizoids are common. Sporangia large, usually black. The main column (columella) is hemispherical, mycelium occurs in large quantities, and it is elongated to fill the lid of the petri dish. Meteorically, the two sperm bags contact fusion to form spores. It is present in soil, fruits, etc., and rarely has pathogenicity in humans, animals, and certain species of plants.
  • R. nigricans ( R. nigricans ) is a fruit of peaches, strawberries, grains, and bread, and is a source of sweet potato soft disease, but it is also known to have strong fumaric acid production capacity.
  • the culture concentrate of the microorganism of genus Rizopus includes lipase, and the lipase means an enzyme that breaks down oil into glycerol and fatty acids.
  • the enzyme treatment of the borage oil is 10 to 80 hours, preferably 15 to 50 hours, and more preferably 20 to 80 hours, with lipase enzyme immobilizing borage oil preheated to a temperature within the range of 10 to 40°C. It can be carried out by enzymatic reaction under the reaction conditions for 30 hours to contact, and the microorganism of the genus Lysopus can be preferably Rhizopus oryzae .
  • the method of manufacturing an enzyme-treated borage oil according to the present invention in a method for producing an enzyme-treated borage oil by enzymatic treatment of borage oil, (1) preheated to a temperature within the range of 10 to 40°C Enzyme treatment step of enzymatic reaction in the enzyme treatment conditions to contact the lipase enzyme immobilized on borage oil for 10 to 80 hours; And (2) a fractionation step in which the enzymatic treatment obtained in the enzymatic treatment step is mixed with 1,3-butylene glycol, followed by layer separation to recover the fraction containing fatty acid.
  • the lipase enzyme in particular, is enzymatically processed in a batch manner using an immobilized enzyme immobilized on a resin, preferably a lipase derived from the genus Lyzopus, after which the enzyme residue containing the resin is separated and filtered and obtained.
  • a resin preferably a lipase derived from the genus Lyzopus
  • the layer is separated to separate the layer containing the fatty acid and the oily layer containing the enzyme-untreated borage oil, and the layer containing the fatty acid is subsequently processed to make a cosmetic.
  • the oily layer containing unenzymatic borage oil can be recovered and introduced again into the enzyme treatment process.
  • the lipase enzyme used for enzyme treatment in particular, the lipase enzyme derived from the microorganism of the genus Lyzopus, the medium and culture conditions and culture time used for the preparation of the enzyme are the same and/or similar to those described above, and repeated descriptions will be avoided.
  • the microorganism of the genus Rhizopus may preferably be Rhizopus oryzae .
  • the enzyme-treated borage oil according to the present invention has a characteristic that the content of free essential unsaturated fatty acids is significantly higher than before the enzyme treatment by enzymatic treatment by the above-described method.
  • the free essential unsaturated fatty acids include gamma-linolenic acid (GLA), alpha-linolenic acid (ALA), linoleic acid (LA) and oleic acid (OA).
  • GLA gamma-linolenic acid
  • ALA alpha-linolenic acid
  • LA linoleic acid
  • OA oleic acid
  • Gamma-linolenic acid is an unsaturated fatty acid component found only in women's milk and some plants, and is a necessary precursor for synthesizing prostaglandins known as active substances in the body.
  • the prostaglandins E1 and E2 which are bioactive substances, are not synthesized, so the essential amino acids and other components necessary for the normal functioning of the body are not well formed, resulting in abnormal immune systems.
  • the free essential unsaturated fatty acid means a form in which fatty acids are not bound to glycerol in the form of glycerides. As the content of free essential unsaturated fatty acids increases, stickiness decreases and skin absorption improves.
  • a composition for improving hair loss containing the above-mentioned enzyme-treated borage oil as an active ingredient may be provided, but it is understood by those skilled in the art that the present invention is not intended to be limited to these. .
  • composition for improving hair loss may be prepared in various formulations such as cream, lotion, emulsion, lotion, essence, mist, gel, pack, mask pack, oil, colorant, soap, body wash, shampoo, rinse, bathing agent, scrub agent, etc. .
  • composition for improving hair loss may further include at least one additive selected from the group consisting of purified water, oil, surfactant, moisturizer, stabilizer, alcohol, emulsifying agent, chelating agent, coloring agent, preservative, and fragrance.
  • the composition of the medium used for Candida Lugosa culture was 2% olive oil, 0.3% yeast extract, 0.3% malt extract, 0.5% peptone, 1% dextrose, pH Prepared at 7.0, and incubated at 30°C for 90 hours.
  • To cultivate Pseudomonas fluorescens, 0.5% peptone, 0.5% yeast extract, and 0.8% salt were added to a nutrient medium (Nutrient broth) to prepare a pH of 7.0, and cultured at 28°C for 32 hours.
  • the medium used for cultivation in Pseudojima is 0.01% glucose, 0.1% olive oil, 0.003% yeast extract, 0.003% malt extract, 0.003% peptone, 0.003% soybean flour, 0.02% ammonium sulfate, 0.001% potassium phosphate, 0.005% magnesium sulfate , 0.001% calcium chloride and 0.0001% sodium chloride were used to prepare pH 7.0 and incubated at 37°C for 24 hours. Thereafter, each strain culture solution was centrifuged at 8000 rpm to precipitate microbial cells to recover only the supernatant, and then slowly added 70% ammonium sulfate at 4°C to precipitate the coenzyme mixture.
  • Adsorptive resins suitable for enzyme immobilization include Amberlite XAD-7, anion exchange resins, porous glass, porous chitosan beads, polypropylene powder, CaCO 3 A lamp is used, and Amberlite XAD-7 resin (Sigma-aldrich), which is relatively stable to double heat and physical impact, is used.
  • the Amberlite XAD-7 resin was washed with ethanol and phosphate buffer solution (pH 7.0), stirred at 37°C for 1 hour and filtered through a filter.
  • Pierce TM Protein is quantified using the method provided by the manufacturer using the Bicinchoninic acid (BCA) Protein Assay kit (Thermoscientific), and the enzyme concentrate is used to adjust the total protein amount to 10 mg/ml using 0.01 M Tris-HCl buffer solution (pH 8.6). Did. After the enzyme concentrate was added to the filtered Amberlite XAD-7 resin, the reaction was performed for 10 hours in a 200° C. 200 rpm shake incubator, and the reaction was centrifuged at 3000 rpm for 5 minutes to separate the Amberlite XAD-7 resin layer. Then, it was washed three times with 0.01 M Tris-HCl buffer solution (pH8.6). After drying it completely with a vacuum desiccator for several hours, it was used as an immobilization enzyme.
  • BCA Bicinchoninic acid
  • Vegetable oil was enzymatically treated using the immobilized enzyme prepared in Preparation Example 1.
  • the enzyme reaction mixture was prepared by diluting 3 g of immobilized enzyme in 57 g of a phosphate buffer solution of pH 7.0 (Sodium phosphate buffer, 50 mM). That is, in the enzymatic treatment, the immobilized enzyme reaction mixture diluted with 5% of the immobilized enzyme in a phosphate buffer solution and vegetable oil (borage oil or camellia oil) are mixed at a ratio of 4:6, and then 60 at 300 rpm and 37°C. It was run for an hour.
  • the vegetable oil is centrifuged at 10,000 rpm for 10 minutes to separate the lipase-immobilized resin, and again, pass through a filtration membrane having a pore size of 0.22 ⁇ m to see the enzyme treatment with the immobilized enzyme. Oil and enzyme-treated camellia oil were obtained, respectively.
  • Example 1 HPLC was performed to analyze the free fatty acid content of the enzymatically treated vegetable oil.
  • Standard products used for this are alpha-linolenic acid (ALA: ⁇ -Linolenic acid, Sigma-aldrich), gamma-linolenic acid (GLA: ⁇ -Linolenic acid, Sigma-aldrich), linoleic acid (LA: Linoleic acid, Sigma-aldrich) and oleic acid.
  • ALA alpha-linolenic acid
  • GLA ⁇ -Linolenic acid, Sigma-aldrich
  • LA Linoleic acid, Sigma-aldrich
  • OA Oleic acid, Sigm-aldrich
  • Solvents used for analysis are HPLC grade isopropanol (DUKSAN) and acetonitrile (Acetonitrile, DAEJUNG), samples and standards are dissolved in isopropanol (Isopropanol, DUKSAN), and then 0.22 ⁇ m membrane filter (membrane filter; PVDF Syringe Filter, 13 mm, FUTECS Co., Ltd.), and analyzed free fatty acids using a C18 column (250 x 4.6 mm, Gemini 5 ⁇ Phenomenex). A sample of 10 ⁇ l was injected at a flow rate of 1.0 ml/min, and measured with ultraviolet light having a wavelength of 210 nm.
  • trifluoroacetic acid in acetonitrile Trifluoroacetic acid, Millipore Co.: 0.005% trifluoroacetic acid in water starts at 80: 20 (v/v) as a gradient condition of the mobile phase
  • fatty acids were analyzed by a gradient analysis for 45 minutes.
  • Table 1 shows the results of analyzing the free fatty acid content of the enzyme-treated vegetable oil.
  • the 5 alpha-reductase inhibition rate of gamma-linolenic acid, linoleic acid, and oleic acid was first tested. After receiving the Sprague Dawley Rat (SD rat) from Samtaco Co., Ltd., after abdominal surgery, the prostate was removed. The prostate was weighed and washed twice with 1x Phosphate-buffered saline (PBS) buffer. The washed prostate was crushed with surgical scissors with the same weight of 0.25 M sucrose solution.
  • PBS Phosphate-buffered saline
  • the pulverized prostate solution was transferred to a homogenizer by a glass homogenizer, homogenized, and centrifuged at 4°C for 20 minutes at 1000 g to recover the prostate supernatant.
  • NADPH Nicotinamide adenine dinucleotide phosphate
  • Each fatty acid dissolved in DMSO was treated with a concentration of 1, 5, 10, 15, and 25 ppm in a reaction mixture using the prostate homogenate.
  • the positive control group only added DMSO to the reaction mixture, and a test mixture without testosterone and ⁇ -NADPH added to the negative control group was separately prepared and stored at 4°C to prevent reaction.
  • the reaction of the 5 alpha-reductase of each reaction mixture was carried out at 37°C for 1 hour, and then using DHT (Dihydrotestosterone) ELISA Kit (MyBioSource), DHT produced by the 5 alpha-reductase according to the manufacturer's test method Was quantified. The results are shown in FIG. 1.
  • the negative control is the amount of DHT inherently present in the prostate of the SD rat, after subtracting it, the amount of newly generated DHT is calculated to calculate the half maximal inhibitory concentration (IC 50 ) of the positive control DHT production. It was calculated and shown in Table 2.
  • gamma-linolenic acid exhibited an IC 50 of about 7.89 times that of oleic acid and about 6.14 times that of linoleic acid, indicating that the activity inhibition rate of 5 alpha-reductase was the best. Therefore, the ratio and content of gamma-linolenic acid among the enzymatically treated vegetable oils are excellent, and the inhibitory efficiency of the 5 alpha-reductase of the enzyme-treated borage oil obtained by enzymatic treatment with lipase isolated and immobilized from lysopus oriose. It was judged to be the best and decided to verify it.
  • the inhibitory capacity of the existing 5 alpha-reductase inhibitors saw palmetto and finasteride and the enzyme-treated vegetable oil was compared.
  • the final concentration by diluting saw palmetto, borage oil, enzyme-treated borage oil, camellia oil and enzyme-treated camellia oil in dimethyl sulfoxide (DMSO) in the reaction mixture through the prostate homogenate prepared by the above method 1, 2.5, 5, 10, 50, 100 ppm, and finasteride was also diluted in DMSO and added to the reaction mixture so that the final concentration was 0.1, 0.25, 0.5, 1, 10 ppm.
  • the 5 alpha-reductase reaction of each reaction mixture was performed at 37° C.
  • Finasteride IC 50 values of type 1 and type 2 5 alpha-reductases have been reported in the range of 300 to 500 nM and 3 to 10 nM, respectively. When converted to ppm, about 0.12 to 0.18 ppm and 0.02 to 0.04 ppm It becomes. When compared with the results of FIG. 1 and Table 2, in this experiment, 0.37 ppm, which is slightly higher than the IC 50 value of type 1 5 alpha-reductase, was recorded, and this value was inhibited for all type 2 5 alpha-reductase, It seems to be similar to the IC 50 value for mainly type 1 5 alpha-reductase.
  • DMEM Dulbecco Modified Eagle Medium
  • FBS Fetal bovine serum
  • the medium used for the culture was removed, and the borage oil and the enzyme-treated borage oil were dissolved in DMSO and treated at concentrations of 1, 10, 100, and 1000 ppm, respectively, at 37°C and 5% CO 2 to 5 Cultured for 24 hours and 24 hours. Thereafter, 20 ⁇ l of a 0.2% MTT solution per each well was added and reacted for 3 hours in a 37°C, 5% CO 2 incubator. After the reaction, all the supernatant was removed and 150 ⁇ l of DMSO was added to dissolve all of the formazan produced at room temperature for 10 minutes, and absorbance was measured at 570 nm using an ELISA reader.
  • borage oil did not significantly affect the growth of cells.
  • enzyme-treated borage oil promoted the growth of dermal papilla cells when treated at 100 ppm or more, which is an enzyme-treated borage oil. This means that it also helps to recover the scalp cells.
  • borage oil, enzyme-treated borage oil and enzyme-treated borage oil and butylene glycol (BG: 1,3-Butylene glycol), propanediol (Propandiol) or glycerin (GC: Glycerin) 1:1
  • BG 1,3-Butylene glycol
  • propanediol propanediol
  • GC glycerin
  • butylene glycol was the only solvent capable of sufficiently dissolving the enzyme-treated borage oil, and as shown in FIG. 4, propanediol and glycerin had distinct layer separation and were excluded from the skin absorption test.
  • a skin absorption capacity experiment was conducted using the Franz diffusion cell method.
  • the absorption power was confirmed using the black mouse skin tissue (C57BL/60, Samtaco), and about 2 x 2 cm wide black mouse skin tissue (C57BL/60) was fixed between the donor and receptor phases.
  • Each sample of 6 ml was administered to the prepared Franz diffusion cell, and the temperature was maintained at about 32.5°C using a constant temperature water bath.
  • Each sample was allowed to be absorbed for 24 hours, and after 24 hours, the receptor phase was recovered and its weight was measured, and the weight of each sample absorbed per hour and skin area was compared and shown in Table 4.
  • the skin absorbing power of borage oil itself increased by 1.46 times by the enzyme treatment, and when the enzyme-treated borage oil was dissolved in butylene glycol, the skin absorbing power of 2.63 times increased to have better skin absorbing power. I could confirm.
  • mice Female C57BL/6 mice, 7 weeks of age, were pre-sale from Samtaco Co., Ltd. and were used for the experiment after a 1 week acclimation period. During the experimental period, the experimental animals were kept in a mouse cage for isolation, and the environmental conditions of the breeding room were maintained at room temperature of 25 ⁇ 3°C, relative humidity of 50 ⁇ 5%, and the illumination cycle was maintained for 12 hours and nights. During this time, tap water and solid feed for experimental animals (Samtaco) were allowed to be consumed freely.
  • mice hair was first removed using a device of a Cutting Length Adjustable Pro Hair Clipper (Joas, JC-5000), and then treated with Niclean hair removal cream (Ildong Pharmaceutical) for 1 minute and washed 3 times with purified water.
  • the epilated mice were bred into 2 control groups and 5 experimental groups of 5 animals, and are shown in Table 5.
  • Testosterone and each sample were applied daily for 27 days after the experiment.
  • Testosterone was dissolved in 50% ethanol at a concentration of 0.5%, and 150 ⁇ l was applied to the back of the mouse to induce hair loss.
  • 150 ⁇ l of each sample was applied.
  • FIG. 5 shows the visual evaluation of hair growth based on the items shown in FIG. 6, and the results were shown graphically in FIG. 7.
  • Fig. 8 shows the result of measuring the length of 50 randomly selected hairs using a dissecting microscope by pulling out a part of the regenerated hair on the 27th day after all the experiments were finished, and regenerating the hair per mouse by re-hairing the regenerated hair. The average of the weights was compared graphically in FIG. 9. As a result of FIG. 5 and FIG.
  • the improvement effect compared to placebo group borage oil was calculated for enzyme-treated borage oil and enzyme-treated borage oil (BG), respectively, and was sequentially indicated in the remarks column.
  • the enzyme-treated borage oil showed a comprehensive improvement of 33%, and in the case of the enzyme-treated borage oil (BG), an overall improvement effect of 41% was confirmed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne : une huile de bourrache traitée par enzyme dans laquelle de l'huile de bourrache contenant une quantité élevée d'acide gamma-linolénique est traitée par enzyme de telle sorte que la 5α-réductase est empêchée et un excellent effet d'amélioration sur la perte de cheveux, c'est-à-dire, une perte de cheveux et un effet de récupération de cellules de follicules pileux est obtenu ; un procédé de préparation de celle-ci et une composition cosmétique la contenant, l'huile de bourrache étant traitée par enzyme avec une enzyme lipase de façon à contenir de l'acide gamma-linolénique libre.
PCT/KR2019/004499 2018-11-30 2019-04-15 Huile de bourrache traitée par enzyme contenant une concentration élevée d'acide gamma-linolénique libre ayant un effet d'amélioration sur la perte de cheveux élevé, son procédé de préparation et composition cosmétique la contenant WO2020111402A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0153169 2018-11-30
KR1020180153169A KR102145112B1 (ko) 2018-11-30 2018-11-30 높은 탈모개선효과를 지닌 고농도 유리 감마-리놀렌산을 포함하는 효소처리 보라지 오일, 이의 제조방법 및 이를 포함하는 화장료 조성물

Publications (1)

Publication Number Publication Date
WO2020111402A1 true WO2020111402A1 (fr) 2020-06-04

Family

ID=70854024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/004499 WO2020111402A1 (fr) 2018-11-30 2019-04-15 Huile de bourrache traitée par enzyme contenant une concentration élevée d'acide gamma-linolénique libre ayant un effet d'amélioration sur la perte de cheveux élevé, son procédé de préparation et composition cosmétique la contenant

Country Status (2)

Country Link
KR (1) KR102145112B1 (fr)
WO (1) WO2020111402A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002363085A (ja) * 2001-05-31 2002-12-18 Maruzen Pharmaceut Co Ltd 抗男性ホルモン剤、及び養毛化粧料、皮脂分泌抑制剤並びに前立腺肥大抑制剤
US20060110475A1 (en) * 2002-09-12 2006-05-25 Marc Schwaller Composition containing in combination at least one bourd oil and at least one borage oil, use thereof as medicine, as dermatological or dermato-cosmetic agent
US8778916B2 (en) * 2005-04-15 2014-07-15 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2015111902A1 (fr) * 2014-01-21 2015-07-30 주식회사 벤스랩 Huile végétale fermentée ayant une teneur élevée en acide gras insaturé essentiel libre, et son procédé de préparation
KR20160008774A (ko) * 2014-07-15 2016-01-25 주식회사 바이오랜드 동백오일 발효물 또는 그 추출물을 함유하는 모발 성장 촉진 또는 탈모 방지용 조성물 및 그 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101125878B1 (ko) * 2005-07-26 2012-03-21 (주)아모레퍼시픽 피부 보습 및 피부 탄력 증진용 화장료 조성물
KR20130059260A (ko) * 2011-11-28 2013-06-05 계명대학교 산학협력단 애기달맞이꽃 추출물을 유효성분으로 포함하는 피부 상태 개선용 조성물
KR101542490B1 (ko) * 2011-12-12 2015-08-07 양정님 야로우, 보리지, 에버라스팅, 레이디스맨틀 및 유칼립투스로 구성된 혼합 추출물을 유효 성분으로 하는 화장료 조성물
KR101415341B1 (ko) * 2013-01-24 2014-07-03 원광대학교산학협력단 달맞이 꽃 종자유 제조방법
KR20160076821A (ko) * 2014-12-23 2016-07-01 주식회사 벤스랩 유리 필수불포화지방산 함량이 높은 발효 식물성 오일 및 그 제조방법
KR101452320B1 (ko) * 2014-03-11 2014-10-22 주식회사 벤스랩 전립선 비대증 및 탈모를 개선하는 ５―알파 환원효소 억제용 발효 동백오일
KR20180103256A (ko) * 2017-03-09 2018-09-19 송석주 달맞이꽃 추출물을 포함하는 화장품용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002363085A (ja) * 2001-05-31 2002-12-18 Maruzen Pharmaceut Co Ltd 抗男性ホルモン剤、及び養毛化粧料、皮脂分泌抑制剤並びに前立腺肥大抑制剤
US20060110475A1 (en) * 2002-09-12 2006-05-25 Marc Schwaller Composition containing in combination at least one bourd oil and at least one borage oil, use thereof as medicine, as dermatological or dermato-cosmetic agent
US8778916B2 (en) * 2005-04-15 2014-07-15 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2015111902A1 (fr) * 2014-01-21 2015-07-30 주식회사 벤스랩 Huile végétale fermentée ayant une teneur élevée en acide gras insaturé essentiel libre, et son procédé de préparation
KR20160008774A (ko) * 2014-07-15 2016-01-25 주식회사 바이오랜드 동백오일 발효물 또는 그 추출물을 함유하는 모발 성장 촉진 또는 탈모 방지용 조성물 및 그 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZANZOTTERA, F.: "Efficacy of a nutritional supplement, standardized in fatty acids and phytosterols, on hair loss and hair health in both women and men", JOURNAL OF COSMETOLOGY & TRICHOLOGY, vol. 3, no. 2, 2017, pages 1 - 7, XP055711916 *

Also Published As

Publication number Publication date
KR20200066089A (ko) 2020-06-09
KR102145112B1 (ko) 2020-08-18

Similar Documents

Publication Publication Date Title
JP5467106B2 (ja) 緑豆発酵−酵素抽出液を含む皮膚老化防止用化粧料組成物
TWI250025B (en) Skin care composition
WO2015137652A1 (fr) Huile de graines fermentées de camellia japonica inhibant la 5-alpha réductase permettant d'atténuer une hypertrophie bénigne de la prostate et la calvitie
JP2009501160A (ja) ヤエナリ乳酸菌培養物及びその製造方法、並びに該培養物を含有する化粧料組成物
JPWO2004085429A1 (ja) Ｉ型コラーゲン及び／又はエラスチン産生促進用組成物
JP2006111560A (ja) セラミド合成促進剤
KR102137252B1 (ko) 락토바실러스 플란타넘 j2k- 27 균주를 이용한 스트레스성 탈모방지용 혼합 발효 추출물 및 그 제조 방법, 그 혼합 발효 추출물을 함유하는 화장료 조성물
JP5223083B2 (ja) 血管新生抑制剤
KR20110042851A (ko) 와송을 이용한 화장료 조성물 및 이를 이용한 비누의 제조방법
KR20160076821A (ko) 유리 필수불포화지방산 함량이 높은 발효 식물성 오일 및 그 제조방법
JP6591963B2 (ja) ラクトバチルス・ペントーサスの化粧品及び薬品への適用
JP2001206835A (ja) コラーゲン合成促進剤及びコラーゲン代謝賦活剤
CN105434195A (zh) 一种具有祛痘且抑制痘痕生成功能的组合物及其应用
CN107635561B (zh) 含有茶皂醇衍生物作为活性成分的组合物
JP2011178770A (ja) 皮膚の色素沈着を抑制する組成物およびその利用
CN101791285B (zh) 一种用于清除面部老年斑的黄皮酰胺复合纳米乳及其制备方法
WO2015111902A9 (fr) Huile végétale fermentée ayant une teneur élevée en acide gras insaturé essentiel libre, et son procédé de préparation
WO2020111402A1 (fr) Huile de bourrache traitée par enzyme contenant une concentration élevée d'acide gamma-linolénique libre ayant un effet d'amélioration sur la perte de cheveux élevé, son procédé de préparation et composition cosmétique la contenant
KR102140333B1 (ko) 높은 피부미백효과를 지닌 고농도 유리 감마-리놀렌산을 포함하는 효소처리 식물성 오일, 이의 제조방법 및 이를 포함하는 화장료 조성물
KR102287543B1 (ko) 두피케어용 화장료 조성물
KR101484685B1 (ko) 신선초 추출물을 활성성분으로 포함하는 조성물
JPH10287582A (ja) 樹皮抽出物からなるヒスタミン遊離抑制剤
WO2010150954A1 (fr) Composition médicinale coréenne traditionnelle capable d'améliorer une dermatite atopique par inhibition de tslp
KR101273027B1 (ko) 캄페롤을 유효성분으로 함유하는 피지 분비 억제용 및항비만용 조성물
CN105636593A (zh) 包含21-o-当归酰基茶皂醇e3的生发或育发促进用组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19891445

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19891445

Country of ref document: EP

Kind code of ref document: A1